Viatris Inc. (Nasdaq: VTRS), a global healthcare company, announces it has acquired Aculys Pharma, Inc., a clinical stage biopharmaceutical company focused on commercializing innovative treatments for neurological conditions. Viatris received rights to develop and commercialize pitolisant and Spydia®, two assets in the Central Nervous System (CNS) therapy area, further expanding Viatris’ portfolio of innovative products in Japan. As part of the transaction, Viatris has acquired exclusive development and commercialization rights in Japan for pitolisant, a selective/inverse agonist of the histamine H3 receptor.
Read the full article: Viatris Completes Acquisition of Aculys Pharma //
Source: https://www.prnewswire.com/news-releases/viatris-completes-acquisition-of-aculys-pharma-including-exclusive-rights-to-pitolisant-in-japan-and-to-spydia-in-japan-and-certain-other-markets-in-the-asia-pacific-region-302585421.html